title: Role of LFB3 in cell-specific cAMP induction of the urokinase-type plasminogen activator gene.
abstract: In previous work we suggested that a kidney-specific transcription factor LFB3 cooperates with cAMP-response element (CRE)-binding proteins within a cAMP regulatory unit comprised of three protein-binding domains and located 3.4 kilobase pairs upstream of the urokinase-type plasminogen activator (uPA) gene in LLC-PK1 cells (Menoud, P.-A., Matthies, R., Hofsteenge, J., and Nagamine, Y. (1993) Nucleic Acids Res. 21, 1845-1852). The two domains contain a CRE-like sequence, and the third domain is recognized by LFB3. The absolute requirement of LFB3 as well as the cooperation among the three domains for cAMP regulation were confirmed by transient transfection assays in F9 teratocarcinoma cells, in which the level of LFB3 was negligible. Suspecting a possible feedback regulation of LFB3 mRNA expression during cAMP-dependent uPA gene induction in LLC-PK1 cells, we measured LFB3 mRNA levels after cAMP treatment and found a strong reduction. This reduction was not due to a change in template activity of the LFB3 gene because run-on transcription showed no significant change in LFB3 gene transcription. RNA synthesis inhibitor-chase experiments indicated that the down-regulation was post-transcriptional. Interestingly, when the inhibitor was added at the same time as cAMP, the cAMP-induced decrease in LFB3 mRNA levels was abrogated, suggesting that ongoing RNA synthesis is required for the decrease. Similar effects on LFB3 mRNA metabolism were observed with all agents that induce uPA mRNA in LLC-PK1 cells, including 12-O-tetradecanoylphorbol-13-acetate, okadaic acid, colchicine, and cytochalasin. We discuss the significance of this regulation in uPA gene expression.
authors.affiliation: Friedrich Miescher Institute, Basel, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Marksitzer
authors.forename: A
authors.initials: A
authors.lastname: Stief
authors.forename: P A
authors.initials: PA
authors.lastname: Menoud
authors.forename: Y
authors.initials: Y
authors.lastname: Nagamine
mesh_terms: D000818:Animals; D001483:Base Sequence; D001665:Binding Sites; D002460:Cell Line; D003078:Colchicine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D003571:Cytochalasin B / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000378:metabolism*; D004790:Enzyme Induction; D004988:Ethers, Cyclic / Q000494:pharmacology; D005246:Feedback; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D051539:Hepatocyte Nuclear Factor 1-beta; D007668:Kidney / Q000378:metabolism*; D008156:Luciferases / Q000096:biosynthesis / Q000378:metabolism; D051379:Mice; D008969:Molecular Sequence Data; D019319:Okadaic Acid; D009838:Oligodeoxyribonucleotides; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000378:metabolism; D015398:Signal Transduction; D016385:TATA Box; D013698:Templates, Genetic; D018243:Teratocarcinoma; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013937:Thymidine Kinase / Q000235:genetics; D014157:Transcription Factors / Q000096:biosynthesis / Q000378:metabolism*; D014158:Transcription, Genetic; D015533:Transcriptional Activation; D014162:Transfection; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D004268:DNA-Binding Proteins; D004988:Ethers, Cyclic; C496496:Hnf1b protein, mouse; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D011994:Recombinant Proteins; D014157:Transcription Factors; D051539:Hepatocyte Nuclear Factor 1-beta; D019319:Okadaic Acid; D003571:Cytochalasin B; D000242:Cyclic AMP; D008156:Luciferases; D013937:Thymidine Kinase; D014568:Urokinase-Type Plasminogen Activator; D013755:Tetradecanoylphorbol Acetate; D003078:Colchicine